Literature DB >> 11721967

A clinicopathological study of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome with special reference to nasal and nasal-type NK/T-cell lymphoma.

N Takahashi1, I Miura, A Chubachi, A B Miura, S Nakamura.   

Abstract

We describe the clinicopathological features of 20 patients with T/natural killer (NK)-cell lymphoma-associated hemophagocytic syndrome (T/NK-LAHS). These patients were categorized into 2 groups according to the onset of hemophagocytic syndrome (HPS). Group 1 developed HPS during the clinical course, typically at the terminal phase of the disease. This group consisted of 7 patients with extranodal lymphoma arising in the nasal cavity, paranasal cavity, tonsils, or skin at presentation. In 5 of these patients, the preferred diagnosis was nasal and nasal-type NK/T-cell lymphoma, whereas the disease diagnoses in the remaining 2 patients were peripheral T-cell lymphoma of unspecified type and angioimmunoblastic T-cell lymphoma, respectively. Group 2 consisted of 13 patients whose disease corresponded to so-called malignant histiocytosis-like lymphoma, which is characterized by HPS at the initial presentation and the infiltration of the liver, spleen, and/or bone marrow without tumor formation. Nine of these 13 cases were found to have common histopathological features: CD56+, Epstein-Barr virus positivity, cytotoxic molecules, and nasal-type NK/T-cell lymphoma. The very poor prognosis of T/NK-LAHS may be partly explained by the finding that nasal and nasal-type NK/T-cell lymphoma, which is resistant to standard chemotherapy, made up the highest percentage (70%) of the cases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11721967     DOI: 10.1007/bf02982065

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  21 in total

1.  Nasal T-cell lymphoma associated with hemophagocytic syndrome.

Authors:  C S Ng; J K Chan; P N Cheng; S C Szeto
Journal:  Cancer       Date:  1986-07-01       Impact factor: 6.860

Review 2.  [Lymphoma-associated hemophagocytic syndrome in adults: a review of the literature].

Authors:  A Chubachi
Journal:  Rinsho Ketsueki       Date:  1994-09

3.  Nodal cytotoxic lymphoma spectrum: a clinicopathologic study of 66 patients.

Authors:  Y Kagami; R Suzuki; H Taji; Y Yatabe; T Takeuchi; S Maeda; E Kondo; M Kojima; T Motoori; Y Mizoguchi; M Okamoto; K Ohnishi; H Yamabe; M Seto; M Ogura; T Koshikawa; T Takahashi; S Kurita; Y Morishima; T Suchi; S Nakamura
Journal:  Am J Surg Pathol       Date:  1999-10       Impact factor: 6.394

4.  Nasal T-cell lymphoma associated with hemophagocytic syndrome. Immunohistochemical and genotypic studies.

Authors:  A Chubachi; H Imai; S Nishimura; M Saitoh; A B Miura
Journal:  Arch Pathol Lab Med       Date:  1992-11       Impact factor: 5.534

5.  A predictive model for aggressive non-Hodgkin's lymphoma.

Authors: 
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

Review 6.  Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management.

Authors:  I J Su; C H Wang; A L Cheng; R L Chen
Journal:  Leuk Lymphoma       Date:  1995-11

7.  Large cell lymphoma with initial presentation in the bone marrow.

Authors:  K F Wong; J K Chan; C S Ng; Y C Chu; L P Li; C H Chan
Journal:  Hematol Oncol       Date:  1992 Sep-Oct       Impact factor: 5.271

8.  [Hemophagocytic syndrome in a patient with immunoblastic lymphadenopathy-like T-cell lymphoma].

Authors:  Y Kawabata; A Chubachi; I Miura; M Saito; T Watanuki; A B Miura
Journal:  Rinsho Ketsueki       Date:  1994-01

9.  Treatment outcome and prognostic factors for primary nasal lymphoma.

Authors:  R Liang; D Todd; T K Chan; E Chiu; A Lie; Y L Kwong; D Choy; F C Ho
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544

10.  Characteristic clinicopathologic features of Epstein-Barr virus-associated peripheral T-cell lymphoma.

Authors:  A L Cheng; I J Su; Y C Chen; W C Uen; C H Wang
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

View more
  23 in total

1.  Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.

Authors:  Y Q Wang; Y Yang; H Y Zhuo; L Q Zou; Y Jiang; M Jiang
Journal:  Med Oncol       Date:  2015-01-09       Impact factor: 3.064

2.  A clinical study of 21 patients with hemophagocytic syndrome in 295 cases diagnosed with nasal type, extranodal nature killer/T cell lymphoma.

Authors:  Na Li; Li Zhang; Jie Liu; Jing Zhang; Hua-Wei Weng; Hong-Yu Zhuo; Li-Qun Zou
Journal:  Cancer Biol Ther       Date:  2017-02-25       Impact factor: 4.742

Review 3.  Lymphoma presenting as secondary HLH: a review with a tale of two cases.

Authors:  Abhimanyu Ghose; Mahender Yellu; Trisha Wise-Draper; Divya Sharma; Julianne Qualtieri; Tahir Latif; Stephen Medlin
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-06-21

4.  L-asparaginase-based regimen as a first-line treatment for newly diagnosed nasal type extranodal natural killer cell/T-cell lymphoma.

Authors:  Shanshan Bu; Fangfang Yuan; Xudong Wei; Qingsong Yin; Yufu Li; Ruihua Mi; Haiping Yang; Hongyi Li; Shoubei Ge; Yanyan Liu; Yongping Song
Journal:  Exp Ther Med       Date:  2016-04-11       Impact factor: 2.447

Review 5.  A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults.

Authors:  Naval Daver; Kenneth McClain; Carl E Allen; Sameer A Parikh; Zaher Otrock; Cristhiam Rojas-Hernandez; Boris Blechacz; Sa Wang; Milen Minkov; Michael B Jordan; Paul La Rosée; Hagop M Kantarjian
Journal:  Cancer       Date:  2017-06-16       Impact factor: 6.860

6.  Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma.

Authors:  Haijun Wen; Huajuan Ma; Qichun Cai; Suxia Lin; Xinxing Lei; Bin He; Sijin Wu; Zifeng Wang; Yan Gao; Wensheng Liu; Weiping Liu; Qian Tao; Zijie Long; Min Yan; Dali Li; Keith W Kelley; Yongliang Yang; Huiqiang Huang; Quentin Liu
Journal:  Nat Med       Date:  2018-01-01       Impact factor: 53.440

7.  A case of adolescent primary adrenal natural killer cell lymphoma.

Authors:  Yoko Mizoguchi; Kazuhiro Nakamura; Shin-Ichiro Miyagawa; Shin-Ichiro Nishimura; Koji Arihiro; Masao Kobayashi
Journal:  Int J Hematol       Date:  2005-05       Impact factor: 2.490

Review 8.  Nasal natural killer (NK)/T-cell lymphoma: clinical, histological, virological, and genetic features.

Authors:  Yasuaki Harabuchi; Miki Takahara; Kan Kishibe; Shigetaka Moriai; Toshihiro Nagato; Hideyuki Ishii
Journal:  Int J Clin Oncol       Date:  2009-07-11       Impact factor: 3.402

Review 9.  Diagnosis and treatment of Epstein-Barr virus-associated natural killer cell lymphoproliferative disease.

Authors:  Keisei Kawa
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

Review 10.  L-asparaginase-Based induction therapy for advanced extranodal NK/T-cell lymphoma.

Authors:  Kosuke Obama; Mitsutoshi Tara; Kiyoshige Niina
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.